TITLE

Ketorolac Tromethamine Nasal Spray (Sprix)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
July 2010
SOURCE
Internal Medicine Alert;7/15/2010, Vol. 32 Issue 13, p101
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the U.S. Food and Drug Administration's (FDA) approval of Roxro Pharma's Sprixâ„¢, a Ketorolac nasal spray.
ACCESSION #
53279868

 

Related Articles

  • Roxro Gets FDA Approval For a Novel Analgesic.  // Chain Drug Review;6/7/2010, Vol. 32 Issue 10, p215 

    The article reports on the approval of Roxro Pharma Inc.'s Sprix, ketorolac tromethamine, nasal spray for use as novel analgesic in the U.S.

  • Roxro Dodges Opioid Traps; Gets Nod for Sprix.  // Bioworld Week;5/24/2010, Vol. 18 Issue 21, p3 

    The article reports on the approval of Roxro Pharma Inc.'s pain product Sprix by the U.S. Food and Drug Administration (FDA).

  • FDA Accepts Roxro's NDA for Intranasal Non-Narcotic Painkiller. Morrison, Trista // BioWorld Today;2/9/009, Vol. 20 Issue 25, p1 

    The article reports on an announcement by Roxro Pharma Inc. that the U.S. Food and Drug Administration (FDA) accepted its new drug application for ROX-888, an intranasal formulation of the non-steroidal anti-inflammatory drug (NSAID) ketorolac. Roxro chief executive officer (CEO) Roberto...

  • FDA Accepts Roxro's NDA for ROX-888.  // Bioworld Week;2/16/2009, Vol. 17 Issue 7, p2 

    The article reports on the announcement of Roxro Pharma Inc. in California that its application for ROX-888, an intranasal formulation of the nonsteroidal anti-inflammatory drug (NSAID) ketoralac, was approved by the U.S. Food and Drug Administration. It states that ketorolac was the only NSAID...

  • Roxro Dodges Opioid, NSAID Traps; 'Smooth' Nod for Sprix. Boggs, Jennifer // BioWorld Today;5/18/2010, Vol. 21 Issue 95, p1 

    This article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve the anti-pain drug Sprix from Roxro Pharma Inc. in 2010. The FDA approved the drug for treating moderate to moderately several pain. The label of the drug shows that it falls in between opioids and...

  • Nasal Spray Analgesic Now Available.  // Journal of Gerontological Nursing;Jul2011, Vol. 37 Issue 7, p16 

    The article states that ketorolac tromethamine (Sprix®) nasal spray for use in management of moderate to moderate-severe pain requiring analgesia at the opioid level is now available commercially and presents dosing information for use with adult patients and older patients.

  • Roxro Adds $42M For Pain Drug Development.  // Bioworld Week;6/18/2007, Vol. 15 Issue 25, p4 

    The article reports that pharmaceutical firm Menlo Park, California-based Roxro Pharma Inc. submitted a $42.7 million in private placement to advance its pain compounds including RXO-888. The firm's lead product candidate ROX-888 is an intranasal version of ketorolac, an injectable nonsteroidal...

  • Roxro's NDA for pain drug accepted for review by FDA.  // PharmaWatch: CNS;Mar2009, Vol. 8 Issue 3, p16 

    The article reports on the acceptance of new drug application (NDA) of Roxro Pharma Inc. for ROX-888, a pain drug, for review by U.S. Food and Drug Administration. It states that ROX-888 is an intranasal formulation of ketorolac which is a non-steroidal anti-inflammatory drug. It adds that the...

  • Roxro Adds $42M Privately To Support Pain Drug Development. Boggs, Jennifer // BioWorld Today;6/13/2007, Vol. 18 Issue 114, p2 

    This section offers financing-related news briefs. Roxro Pharma Inc. brought in $42.7 million in a private placement to support ROX-888, an intranasal analgesic. Acusphere entered definitive agreements with investors in a move to raise $20 million in gross proceeds in a registered direct...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics